Top

Published in:

01-04-2008 | Original Article

Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma

Authors: Paul Neeson, Zhen Kun Pan, Yvonne Paterson

Published in: Cancer Immunology, Immunotherapy | Issue 4/2008

Abstract

Follicular lymphoma (FL) is a disease that responds to current treatment regimens; however, patients in general relapse with increasingly refractory disease. Idiotype-based vaccines are currently under trial for the treatment of FL. These vaccines comprise the patient’s BCR idiotype (Id) as the tumor antigen conjugated to the protein carrier Keyhole Limpet Hemocyanin (KLH); however, other protein carriers may enhance the immune response to the lymphoma Id. In this study we investigated whether an alternate carrier, Listeriolysin O (LLO), would amplify the immune response to Id protein and provide better protection against challenge by 38C13 murine lymphoma. The Id-LLO vaccine compared favorably against Id-KLH in tumor-protection studies and both vaccines provided systemic immunity against 38C13 lymphoma. However, the immune response to the two conjugates was different in that Id-LLO induced a more powerful Th1 response characterized by high titer IgG2a anti-Id antibodies after one immunization and the presence of CD4 cells secreting IFN-γ. In vivo studies demonstrated that immune serum contributed to the anti-lymphoma efficacy seen following Id-LLO immunization. Interestingly, Id-LLO immunized mice, when challenged twice with 38C13 lymphoma provided better protection against challenge by the BCR loss variant 38C13-V2, suggesting that Id-LLO immunized mice have more potential to develop epitope spreading than Id-KLH. In conclusion, Id-LLO compared favorably against Id-KLH in its anti-lymphoma efficacy. Furthermore, Id-LLO induced a more potent humoral and cell-mediated immune response and promoted epitope spreading after lymphoma challenge. Thus, anti-Id vaccines incorporating LLO may be a better therapeutic option for treatment of B-cell lymphoma.

Available only for authorised users

Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92:1240–1251PubMedCrossRef

Ries LAG, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds) (2006) SEER Cancer Statistics Review, 1975–2003. National Cancer Institute. Bethesda

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423PubMedCrossRef

Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B (2003) Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin’s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2:1183–1193PubMed

Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949–954PubMedCrossRef

Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947PubMedCrossRef

Jazirehi AR, Bonavida B (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24:2121–2143PubMedCrossRef

Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B (2005) Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65:264–276PubMed

Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362–371PubMed

10.

Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW (2006) Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Rev Vaccines 5:381–394PubMedCrossRef

11.

Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC (1986) Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. J Immunol 137:3019–3024PubMed

12.

Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R (1986) Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 136:1123–1130PubMed

13.

Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R (1987) Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood 69:199–210PubMed

14.

Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R (1992) Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80:1502–1510PubMed

15.

Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R (1998) Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 92:1184–1190PubMed

16.

Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R (1993) Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann N Y Acad Sci 690:385–387PubMedCrossRef

17.

Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 89:3129–3135PubMed

18.

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF (2006) Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol 24:3107–3112PubMedCrossRef

19.

Caspar CB, Levy S, Levy R (1997) Idiotype vaccines for non-Hodgkin’s lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 90:3699–3706PubMed

20.

Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209–1215PubMedCrossRef

21.

Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171–1177PubMedCrossRef

22.

Hurvitz SA, Timmerman JM (2005) Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId. Expert Opin Biol Ther 5:841–852PubMedCrossRef

23.

Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R (1990) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145:1029–1036PubMed

24.

Kwak LW, Campbell M, Levy R (1991) Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detect Prev 15:323–325PubMed

25.

Villanueva MS, Sijts AJ, Pamer EG (1995) Listeriolysin is processed efficiently into an MHC class I-associated epitope in Listeria monocytogenes-infected cells. J Immunol 155:5227–5233PubMed

26.

Vijh S, Pamer EG (1997) Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. J Immunol 158:3366–3371PubMed

27.

Vijh S, Pilip IM, Pamer EG (1999) Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection. Infect Immun 67:1303–1309PubMed

28.

Lara-Tejero M, Pamer EG (2004) T cell responses to Listeria monocytogenes. Curr Opin Microbiol 7:45–50PubMedCrossRef

29.

Pamer EG (2004) Immune responses to Listeria monocytogenes. Nat Rev Immunol 4:812–823PubMedCrossRef

30.

Paterson Y, Maciag PC (2005) Listeria-based vaccines for cancer treatment. Curr Opin Mol Ther 7:454–460PubMed

31.

Peng X, Treml J, Paterson Y (2006) Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Cancer Immunol Immunother 56:797–806PubMedCrossRef

32.

Bergman Y, Haimovich J (1977) Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 7:413–417PubMedCrossRef

33.

Bergman Y, Haimovich J, Melchers F (1977) An IgM-producing tumor with biochemical characteristics of a small B lymphocyte. Eur J Immunol 7:574–579PubMedCrossRef

34.

Carroll WL, Starnes CO, Levy R, Levy S (1988) Alternative V kappa gene rearrangements in a murine B cell lymphoma. An explantation for idiotypic heterogeneity. J Exp Med 168:1607–1620PubMedCrossRef

35.

Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R (1988) Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. J Immunol 141:333–339PubMed

36.

Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R (1985) Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4:191–209PubMedCrossRef

37.

Eshhar Z, Blatt C, Bergman Y, Heimovich J (1979) Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol 122:2430–2434PubMed

38.

Trebak M, Chong JM, Herlyn D, Speicher DW (1999) Efficient laboratory-scale production of monoclonal antibodies using membrane-based high-density cell culture technology. J Immunol Methods 230:59–70PubMedCrossRef

39.

Andrew SM, Titus JA (1997) Purification of IgM. In: Kruisbeek A, Coligan J, Marguiles D, Shevach E, Strober W (eds) Current protcols in immunology, Unit 2.9

40.

Andrew SM, Titus JA (1997) Purification of IgG. Alternate protocol 1: affinity chromatography using protein G sepharose. In: Kruisbeek A, Coligan J, Marguiles D, Shevach E, Strober W (eds) Current protcols in immunology, Unit 2.7

41.

Holmes K, Lants L, Fowlkes B, Schmid I, Giorgi J (2003) Support protocol 1: labeling antibody with Fluorescein Isothiocyanate (FITC). In: Kruisbeek A, Coligan J, Marguiles D, Shevach E, Strober W (eds) Current protocols in immunology, Unit 5.3. Wiley, New York

42.

Glomski IJ, Gedde MM, Tsang AW, Swanson JA, Portnoy DA (2002) The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol 156:1029–1038PubMedCrossRef

43.

Nato F, Reich K, Lhopital S, Rouyre S, Geoffroy C, Mazie JC, Cossart P (1991) Production and characterization of neutralizing and nonneutralizing monoclonal antibodies against listeriolysin O. Infect Immun 59:4641–4646PubMed

44.

Biragyn A, Kwak L (2006) Models for lymphoma. In: BB, Coligan J, Marguilies D, Shevach E, Strober W, Brown P, Donovan J (eds) Unit 20.26. Wiley, New York

45.

Kingdon GC, Sword CP (1970) Biochemical and immunological effects of Listeria monocytogenes Hemolysin. Infect Immun 1:363–372PubMed

46.

Portnoy DA, Jacks PS, Hinrichs DJ (1988) Role of hemolysin for the intracellular growth of Listeria monocytogenes. J Exp Med 167:1459–1471PubMedCrossRef

47.

Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM (1987) Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 166:1484–1498PubMedCrossRef

48.

Heufler C, Koch F, Schuler G (1988) Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 167:700–705PubMedCrossRef

49.

Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202–210PubMed

50.

Kwak LW, Young HA, Pennington RW, Weeks SD (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93:10972–10977PubMedCrossRef

51.

Bercovici N, Duffour MT, Agrawal S, Salcedo M, Abastado JP (2000) New methods for assessing T-cell responses. Clin Diagn Lab Immunol 7:859–864PubMedCrossRef

52.

Tanaka Y, Ohdan H, Onoe T, Asahara T (2004) Multiparameter flow cytometric approach for simultaneous evaluation of proliferation and cytokine-secreting activity in T cells responding to allo-stimulation. Immunol Invest 33:309–324PubMedCrossRef

53.

Neeson P, Paterson Y (2004) A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma. Cytometry A 60:8–20PubMedCrossRef

54.

Winn HJ (1972) In vivo methods for the assessment of antibody-mediated tumor immunity. Natl Cancer Inst Monogr 35:13–18PubMed

55.

Kwak LW, Campbell MJ, Zelenetz AD, Levy R (1991) Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood 78:2768–2772PubMed

56.

Syrengelas AD, Levy R (1999) DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 162:4790–4795PubMed

57.

Timmerman JM, Levy R (2000) Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 164:4797–4803PubMed

58.

Cha SC, Kwak LW, Ruffini PA, Qin H, Neelapu S, Biragyn A (2006) Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. J Immunol Methods 312:79–93PubMedCrossRef

59.

Kwak LW, Campbell MJ, Zelenetz AD, Levy R (1990) Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood 76:2411–2417PubMed

Title: Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma
Authors: Paul Neeson
Zhen Kun Pan
Yvonne Paterson
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0388-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow

A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis

Saccharomyces cerevisiae, the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice

A simple but effective cancer vaccine consisting of an antigen and a cationic lipid

Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model

Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10–11, 2007

Keynote webinar | Spotlight on antibody–drug conjugates in cancer